HKMPY
Price
$56.20
Change
-$0.71 (-1.25%)
Updated
Jun 18 closing price
Capitalization
5.93B
HROW
Price
$31.58
Change
+$0.23 (+0.73%)
Updated
Jun 27, 10:40 AM (EDT)
Capitalization
467.85M
46 days until earnings call
Interact to see
Advertisement

HKMPY vs HROW

Header iconHKMPY vs HROW Comparison
Open Charts HKMPY vs HROWBanner chart's image
Hikma Pharmaceuticals
Price$56.20
Change-$0.71 (-1.25%)
Volume$251
Capitalization5.93B
Harrow
Price$31.58
Change+$0.23 (+0.73%)
Volume$5.54K
Capitalization467.85M
HKMPY vs HROW Comparison Chart in %
Loading...
HROW
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
HKMPY vs. HROW commentary
Jun 27, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is HKMPY is a Hold and HROW is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 27, 2025
Stock price -- (HKMPY: $56.20 vs. HROW: $31.35)
Brand notoriety: HKMPY and HROW are both not notable
Both companies represent the Pharmaceuticals: Other industry
Current volume relative to the 65-day Moving Average: HKMPY: 53% vs. HROW: 77%
Market capitalization -- HKMPY: $5.93B vs. HROW: $467.85M
HKMPY [@Pharmaceuticals: Other] is valued at $5.93B. HROW’s [@Pharmaceuticals: Other] market capitalization is $467.85M. The market cap for tickers in the [@Pharmaceuticals: Other] industry ranges from $77.48B to $0. The average market capitalization across the [@Pharmaceuticals: Other] industry is $3.8B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

HKMPY’s FA Score shows that 1 FA rating(s) are green whileHROW’s FA Score has 1 green FA rating(s).

  • HKMPY’s FA Score: 1 green, 4 red.
  • HROW’s FA Score: 1 green, 4 red.
According to our system of comparison, HROW is a better buy in the long-term than HKMPY.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

HROW’s TA Score shows that 2 TA indicator(s) are bullish.

  • HROW’s TA Score: 2 bullish, 6 bearish.

Price Growth

HKMPY (@Pharmaceuticals: Other) experienced а 0.00% price change this week, while HROW (@Pharmaceuticals: Other) price change was -0.54% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was +0.19%. For the same industry, the average monthly price growth was +14.45%, and the average quarterly price growth was +91.39%.

Reported Earning Dates

HKMPY is expected to report earnings on Mar 19, 2025.

HROW is expected to report earnings on Aug 12, 2025.

Industries' Descriptions

@Pharmaceuticals: Other (+0.19% weekly)

Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
HKMPY($5.93B) has a higher market cap than HROW($468M). HROW has higher P/E ratio than HKMPY: HROW (39.53) vs HKMPY (32.15). HKMPY YTD gains are higher at: 14.408 vs. HROW (-6.557). HKMPY has higher annual earnings (EBITDA): 489M vs. HROW (9.95M). HKMPY has more cash in the bank: 292M vs. HROW (82.8M). HROW has less debt than HKMPY: HROW (191M) vs HKMPY (1.28B). HKMPY has higher revenues than HROW: HKMPY (2.52B) vs HROW (130M).
HKMPYHROWHKMPY / HROW
Capitalization5.93B468M1,268%
EBITDA489M9.95M4,913%
Gain YTD14.408-6.557-220%
P/E Ratio32.1539.5381%
Revenue2.52B130M1,936%
Total Cash292M82.8M353%
Total Debt1.28B191M672%
FUNDAMENTALS RATINGS
HKMPY vs HROW: Fundamental Ratings
HKMPY
HROW
OUTLOOK RATING
1..100
3176
VALUATION
overvalued / fair valued / undervalued
1..100
16
Undervalued
76
Overvalued
PROFIT vs RISK RATING
1..100
10051
SMR RATING
1..100
9297
PRICE GROWTH RATING
1..100
4942
P/E GROWTH RATING
1..100
9211
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

HKMPY's Valuation (16) in the null industry is somewhat better than the same rating for HROW (76) in the Pharmaceuticals Other industry. This means that HKMPY’s stock grew somewhat faster than HROW’s over the last 12 months.

HROW's Profit vs Risk Rating (51) in the Pharmaceuticals Other industry is somewhat better than the same rating for HKMPY (100) in the null industry. This means that HROW’s stock grew somewhat faster than HKMPY’s over the last 12 months.

HKMPY's SMR Rating (92) in the null industry is in the same range as HROW (97) in the Pharmaceuticals Other industry. This means that HKMPY’s stock grew similarly to HROW’s over the last 12 months.

HROW's Price Growth Rating (42) in the Pharmaceuticals Other industry is in the same range as HKMPY (49) in the null industry. This means that HROW’s stock grew similarly to HKMPY’s over the last 12 months.

HROW's P/E Growth Rating (11) in the Pharmaceuticals Other industry is significantly better than the same rating for HKMPY (92) in the null industry. This means that HROW’s stock grew significantly faster than HKMPY’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
HROW
RSI
ODDS (%)
Bearish Trend 1 day ago
86%
Stochastic
ODDS (%)
Bearish Trend 1 day ago
88%
Momentum
ODDS (%)
Bearish Trend 1 day ago
85%
MACD
ODDS (%)
Bearish Trend 1 day ago
81%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
82%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
82%
Advances
ODDS (%)
Bullish Trend 4 days ago
84%
Declines
ODDS (%)
Bearish Trend 1 day ago
81%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
82%
Aroon
ODDS (%)
Bullish Trend 1 day ago
80%
View a ticker or compare two or three
Interact to see
Advertisement
HROW
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
DIFGX12.26N/A
N/A
MFS Diversified Income R4
BMRRX36.36N/A
N/A
BlackRock Mid-Cap Growth Equity R
TEEAX10.23N/A
N/A
RBC Small Cap Core A
GVCAX10.88N/A
N/A
Gabelli Value 25 AAA
BAHAX17.36N/A
N/A
Brown Advisory WMC Strat Eurp Eq Adv

HKMPY and

Correlation & Price change

A.I.dvisor tells us that HKMPY and HROW have been poorly correlated (+23% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that HKMPY and HROW's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To HKMPY
1D Price
Change %
HKMPY100%
N/A
HROW - HKMPY
23%
Poorly correlated
-0.63%
PAIOF - HKMPY
22%
Poorly correlated
N/A
CXXIF - HKMPY
22%
Poorly correlated
-3.33%
HYPMY - HKMPY
14%
Poorly correlated
-2.13%
ETST - HKMPY
10%
Poorly correlated
+1.33%
More